Lorenzo Nibid
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (62)
Year:
2026
Background/Objectives: Thymomas are the most common tumors of the anterior mediastinum. While early-stage disease often has a favorable prognosis, therapeutic options in advanced stages remain limited. Moreover, the molecular profile of thymomas is still poorly characterized. In the present study, we explored the presence of targetable mutations and programmed death-ligand 1 (PD-L1) expression in a cohort of surgically resected thymomas. Furthermore, we investigated the correlation between PD-L1 expression, histological subtype, and risk of recurrence in patients who underwent curative-intent thymectomy. Methods: Mutational profiling was performed using a DNA-based NGS Cancer Panel of 16 genes. PD-L1 expression was evaluated via Tumor Proportion Score (TPS), and thymomas with TPS ≥ 50% were identified as high expressors. The associations with histological subtype and disease-free survival (DFS) were analyzed using logistic regression, Cox proportional hazards models, and Kaplan–Meier survival curves. Results: In our study, 2/37 (5.4%) of tested neoplasms (type AB and B2 thymoma) reported as a PIK3CA mutation; no other targetable mutations were observed. Moreover, high PD-L1 expression (≥50%) was reported in (15/37) 40.5% of patients and was significantly associated with aggressive histological subtypes (B2 and B3) (p < 0.001). Logistic regression analysis showed that high PD-L1 expression was a significant predictor of aggressive histology (McFadden’s R2 = 0.268, p < 0.001), with an odds ratio of 15.5 (95% CI: 2.9–83.4; p = 0.001). During follow-up, 5/37 (13.5%) of patients experienced disease recurrence; however, no significant difference in DFS was found between high and low PD-L1 expression groups. Conclusions: Our data confirm the presence of PIK3CA mutations in thymomas and encourage the exploration the potential role of molecular target therapy in this setting. Moreover, we underlined that high PD-L1 expression level is associated with more aggressive thymoma subtypes and may have a role as a prognostic biomarker. These findings support the need for further studies on the potential role of molecular and predictive pathology in thymic epithelial tumors.
Year:
2026
Year:
2026
Hodgkin lymphoma (HL) is a type of lymphoma, characterized by the presence of abnormal Reed‐Sternberg cells. It typically affects lymph nodes, generally in the upper body (such as neck, chest, and armpits). It can also involve the spleen, liver, and bone marrow. In the literature, there are sporadic cases of atypical localization of HL. The aim of this article is to report a peculiar case of HL in a 55‐year‐old male presenting with primary epitrochlear lymphadenopathy as the only localization of disease, also performing a literature review on this atypical presentation. We also summarized the possible underlying malignant pathologies that arise from the soft tissues of the upper limb adjacent to the elbow.
Year:
2025
Background: Approximately 25.0% of metastatic prostate cancer patients harbour DNA damage repair mutations, including BRCA1 and BRCA2, which are actionable targets for poly(ADP-ribose) polymerase (PARP) inhibitors. Accurate detection of BRCA1/2 mutations is critical for guiding targeted therapies, but crucial pre-analytical factors, such as tissue storage duration and DNA fragmentation, drastically affect the reliability of next-generation sequencing (NGS) using real-world diagnostic specimens. Methods: This multicentre study analysed 954 formalin-fixed paraffin-embedded tissue samples from 11 centres, including 559 biopsies and 395 surgical specimens. This study examined the impact of storage duration ( 2 years) and DNA parameters (concentration and fragmentation index) on NGS success rates. Logistic regression and Cox regression analyses were used to assess correlations between these factors and sequencing outcomes. Results: NGS success rates decreased significantly with longer storage, from 87.8% ( 2 years). Samples with higher DNA concentrations and fragmentation indexes had higher success rates (p < 0.001). Surgical specimens had superior success rates (83.3%) compared with biopsies (72.8%) due to better DNA quality. The DNA degradation rate was more pronounced in older samples, underscoring the negative impact of extended storage. Conclusions: Timely testing of BRCA1/2 mutations is critical for optimizing the identification of prostate cancer patients eligible for PARP inhibitors. Surgical specimens provide more reliable results than biopsies and minimizing the storage duration significantly enhances testing outcomes. Standardizing pre-analytical and laboratory procedures across centres is essential to ensure personalized treatments and improve patient outcomes.
Year:
2025
Importance Only a small fraction of patients with advanced non−small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy. Objective To develop a supervised deep learning−based ICI response prediction method; evaluate its performance alongside other known predictive biomarkers; and assess its association with clinical outcomes in patients with advanced NSCLC. Design, Setting, and Participants This multicenter cohort study developed and independently validated a deep learning−based response stratification model for predicting ICI treatment outcome in patients with advanced NSCLC from whole slide hematoxylin and eosin–stained images. Images for model development and validation were obtained from 1 participating center in the US and 3 in the European Union (EU) from August 2014 to December 2022. Data analyses were performed from September 2022 to May 2024. Exposure Monotherapy with ICIs. Main Outcomes and Measures Model performance measured by clinical end points and objective response rate (ORR) differentiation power vs other predictive biomarkers, ie, programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), and tumor-infiltrating lymphocytes (TILs). Results A total of 295 581 image tiles from 958 patients (mean [SD] age, 66.0 [10.6] years; 456 [48%] females and 502 [52%] males) treated with ICI for NSCLC were included in the analysis. The US-based development cohort consisted of 614 patients with median (IQR) follow-up time of 54.5 (38.2-68.1) months, and the EU-based validation cohort, 344 patients with 43.3 (27.4-53.9) months of follow-up. The ORR to ICI was 26% in the developmental cohort and 28% in the validation cohort. The deep learning model’s area under the receiver operating characteristic curve (AUC) for ORR was 0.75 (95% CI, 0.64-0.85) in the internal test set and 0.66 (95% CI, 0.60-0.72) in the validation cohort. In a multivariable analysis, the deep learning model’s score was an independent predictor of ICI response in the validation cohort for both progression-free (hazard ratio, 0.56; 95% CI, 0.42-0.76; P < .001) and overall survival (hazard ratio, 0.53; 95% CI, 0.39-0.73; P < .001). The tuned deep learning model achieved a higher AUC than TMB, TILs, and PD-L1 in the internal set; in the validation cohort, it was superior to TILs and comparable with PD-L1 (AUC, 0.67; 95% CI, 0.60-0.74), with a 10-percentage point improvement in specificity. In the validation cohort, combining the deep learning model with PD-L1 scores achieved an AUC of 0.70 (95% CI, 0.63-0.76), outperforming either marker alone, with a response rate of 51% compared to 41% for PD-L1 (≥50%) alone. Conclusions and Relevance The findings of this cohort study demonstrate a strong and independent deep learning−based feature associated with ICI response in patients with NSCLC across various cohorts. Clinical use of this deep learning model could refine treatment precision and better identify patients who are likely to benefit from ICI for treatment of advanced NSCLC.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (44)
Alessandro Di Federico
University of Bologna
Pasquale Pisapia
Assistant Professor of Anatomic Pathology
University of Naples Federico II
Umberto Malapelle
-
Bruno Beomonte Zobel
Head of the Department
Università Campus Bio-Medico
Giuseppe Tonini
Full Professor of Medical Oncology
Campus Bio Medico University Hospital
Marco Gaetano Tucci
Associate Professor
University of Bari
Matteo Tortora
Assistant Professor
University of Genova
Vincenzo L'Imperio
Assistant Professor
Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca
David J. Pinato
Imperial College London
Cristiana Bellan
MD, PhD, Associated professor
University of Siena
Bruno Vincenzi
Professor of Medical Oncology
Università Campus Bio-Medico
Alessandro Gambella
University of Pittsburgh
Rosa Sicilia
Assistant Professor (RTDA)
Università Campus Bio-Medico di Roma
Stefano Marletta
University of Verona
Maria Grazia Vitale
Fondazione IRCCS Istituto Nazionale dei Tumori
Sebastiano Buti
Ricercatore a contratto tipo B
University of Parma
Alessandro Caputo
-
maria rosaria raspollini
University of Florence
Marco Ferrari
Associate Professor
University of Padova
Luca Mastracci
Consultant - Assistant Professor
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro
Alessio Cortellini
Imperial College London
Andrea Vecchione
-
Michele Fiore
Università Campus Bio-Medico di Roma
Maria Giuseppa Vitale
-
Giuseppe Ingravallo
Prof
University of Bari Aldo Moro
Silvia Uccella
IRCCS Humanitas Research Hospital
Rosario Francesco Grasso
-
Paolo Marchetti
Sapienza University of Rome
Giuseppe Nicolò Fanelli
University of Pisa
Michele Ghidini
Docenti di ruolo di IIa fascia
University of Insubria
Francesco Pantano
National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)
Ministero dell’Istruzione, dell’Università e della Ricerca
Alfonso Baldi
Professore Associato in Anatomia Patologica
Link Campus University
Dario de Biase
Associate professor equivalent to senior biologist
University of Bologna
Melissa Bersanelli
Adjunct Professor in Medical Oncology
University of Parma
Fabio Pagni
University of Milano-Bicocca
Giancarlo Troncone
-
olga nigro
Fondazione IRCCS Istituto Nazionale dei Tumori
Alessandro Russo
Humanitas University
Albino Eccher
-
MICHELE DE TURSI
ASSOCIATE PROFESSOR
University "G. d'Annunzio"
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
Giuseppe Perrone
Università Campus Bio-Medico di Roma
Antonio D'Alessio
King's College Hospital
Nicola Fusco
Director
University of Milan
Make your next move.
Prepare your application
Review drafts before you send them.